exenatide placebo

Exenatide placebo, specifically the version utilized by GSK in clinical research, is a sterile saline solution used as a pharmacologically inactive control in trials evaluating exenatide and other GLP-1 receptor agonists. It is administered via subcutaneous injection to match the delivery method of the active drug. In the context of GSK's Phase 4 crossover study (NCT02073110), this placebo was used to establish a baseline for regional brain activity and nausea symptoms in healthy volunteers susceptible to motion sickness, allowing researchers to isolate the central mechanisms of nausea associated with short-acting (exenatide) and long-acting (albiglutide) GLP-1 receptor agonists using functional magnetic resonance imaging (fMRI).

Other names

saline placebosterile salineexenatide matching placebo